skip to Main Content

Board of directors

Peter Hentschel – Chairman

Peter has more than 30 years  international experience within the Health Care and Life Science  industry. Previous positions include CEO of Etac AB, Vice President of SCA Hygienes Incontinence Division and Senior Vice President of Mölnlycke Health Cares Wound Care and Surgical Divisions. Peter was actively involved in the sale of MHC to Apax  in 2005. During the past 12 years Peter has had Chairman positions and board memberships in several listed /non listed companies. Presently, in addition to being Chairman of Reapplix, he is the Chairman of RLS Global AB and member of the board of Lumina Adhesives AB.

Ulf Rosén

Ulf’s previous positions include President & CEO of NeoPharma AB; General Manager of Fresenius-Kabi AB; Executive Vice President Global Nutrition Division at Fresenius-Kabi and President & CEO of Pharmacia & Upjohn AS. In addition, he has, for the past 18 years held Chairman positions and board memberships with several listed/non-listed life science companies in Scandinavia including the Trade Association, IML. Ulf has founded and exited several companies in the life science sector. Currently he is a Board member of Acarix AB/Acarix A/S, Curasight ApS, Lobsor Holding AB (Chairman), Intrance Holding AB (Chairman) and Intrance Medical Systems Inc. (Chairman).

Søren Møller

Søren joined Novo A/S in 2011 as Managing Investment Director of Novo Seeds. Søren obtained his MSc degree from the Technical University of Denmark in 1993 and his PhD degree in molecular biology in 1997 from the Technical University of Denmark. In addition, Søren has academic training as postdoctoral fellow at Stanford University School of Medicine. Prior to joining Novo Seeds, Søren served as global manager of Genomics at Novozymes. Before Novozymes, Søren was CSO and Vice President of R&D at Exiqon A/S. During Søren’s tenure, Exiqon completed an IPO and the company was acquired by Qiagen in 2016. Previously, Søren worked in cancer drug development as head of Lead Identification at BioImage and as research scientist at Novo Nordisk. Søren serves on the Board of Directors of EpiTherapeutics (sold to Gilead), AMRA, Biosyntia, Reapplix and Northsea Therapeutics. Since 2008, Søren has been board member of Danish Biotech (the Association of Biotechnology Industries in Denmark) and DVCA (Danish Venture Capital Association).

Tonni Bülow-Nielsen

Tonni has extensive medical device and life science experience and his previous positions include being CEO of Nordic Medical Group A/S, President, ELA Medical (Canada & South America), a part of Sanofi, Global Marketing Director for St. Jude Medical (Los Angeles, USA, and Japan), BU Director for St. Jude Medical EEMEA (Brussels, Belgium), Country Manager for Guidant Nordic Area and Sales Manager for Danica Biomedical. His educational background was as a medico engineer and he holds an executive MBA from the Scandinavian International Management Institute. In Vækstfonden, he is responsible for the business development of the MedTech portfolio and has several active board memberships including Fluimedix, Advalight, TeesuVac, AnyBody Technology and FBC devices.

Rasmus Lundquist

Rasmus is the Chief Scientific Officer and a founder of Reapplix. He is a highly experienced entrepreneur with +15 years of experience and a MSc. in biology and immunology from Copenhagen University and a graduate certificate in Biodesign from Stanford University. He is highly experienced and widely published in the development of in-vitro assays for the characterization of growth factor containing products. He co-founded RAM Biotech Aps in 2001 prior to his involvement with Reapplix.

Back To Top